Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Bevanolol hydrochloride tablets in essential hypertension
ChiCTR2100052370Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Qinzhou
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevantolol in essential hypertension, sponsored by The First People's Hospital of Qinzhou. Primary endpoint: Change in sitting diastolic blood pressure from baseline after bevanolol administration. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
bevantolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2100052370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052370.